Antibiotics in Addition to Systemic Corticosteroids for Acute Exacerbations of Chronic Obstructive Pulmonary Disease Johannes M.A. Daniels; Dominic snijders;

Slides:



Advertisements
Similar presentations
Antimicrobial Prescribing in the Management of COPD
Advertisements

Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomized control trial (BMJ. 2010;341:c5462)
Infection in COPD Pulmonology Subspeciality Rounds (12/11/2008)Dr.Krock Dr.Vysetti Dr.Vysetti.
Horng H Chen MD on behalf of the NHLBI Heart Failure Clinical Research Network Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF):
Diuretic Strategies in Patients with Acute Decompensated Heart Failure Diuretic Optimization Strategies Evaluation (DOSE) trial.
Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Intravenous Maintenance Fluids Friedman JN, Beck CE, DeGroot J, Geary DF, Sklansky.
1 Antibiotic Prevention of Acute Exacerbations of COPD Dr Farhad Abbasi Infectious Diseases Specialist.
Center for Excellence in Critical Care Am J Respir Crit Care Med 2005;171:242-8 Hydrocortisone Infusion for Severe Community- acquired Pneumonia A Preliminary.
Pneumonia & Respiratory Tract Infection: Antibiotic risk for Clostridium difficile Kieran Hand*, Adil Ahmed †, Adriana Basarab ¶, Whitney Chow †, Nick.
Managing acute exacerbations of COPD in primary care.
Highly sensitive C-reactive protein levels in Iranian patients with pulmonary complications of sulfur mustard poisoning & its correlation with severity.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2011.
Office of Drug Evaluation IV, CDER FDA/IDSA/ISAP Workshop 4/16/04 Overview of PK-PD in Drug Development Programs: FDA Perspective FDA/IDSA/ISAP Workshop.
COPD MANAGEMENT FALLS SHORT AT RCRMC Jean Solomon, M.D.
COPD Management of Stable COPD Shyam Rao May 2014.
HIGH DOSES OF VITAMIN D TO REDUCE EXACERBATION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A RANDOMIZED TRIAL An Lehouck, PhD; Chantal Mathieu, MD, PhD;
BY MELISSA JAKUBOWSKI PULMONARY DISEASE TREATMENT CONCERNING COPD.
1 Tolvaptan for the Treatment of Hyponatremia Aliza Thompson, MD Medical Officer Cardiovascular and Renal Drugs Advisory Committee Meeting June 25, 2008.
1 Selection of  in Clinical Trials of Antimicrobial Therapy - Acute Exacerbation of Chronic Bronchitis Susan D. Thompson, M.D. February 19, 2002.
Immunoglobulin plus prednisolone in severe Kawaski disease (RAISE study) Steph Borg 22 November 2012 SCH Journal Club.
Sarah Struthers, MD March 19, 2015
Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group,
Serum procalcitonin and C-reactive protein in children with community- acquired pneumonia K.Gogvadze, I.Guramishvili, I.Chkhaidze, K.Nemsadze, T.Maglakelidze.
Duality of interests B.M. Mayosi has received research grants from AstraZeneca, Cadila Pharma, Novartis, Pfizer, Roche, and Servier.
Development of Antibiotics for Otitis Media: Past, Present, and Future Janice Soreth, M.D. Director Division of Anti-Infective Drug Products.
Incidence of hospitalisations in both groups Incidence of documented infections Abstract Problem statement: Patients on cancer chemotherapy are at substantial.
TEMPLATE DESIGN © Noninvasive mechanical ventilation in the weaning of patients with respiratory failure due to COPD.
AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.
BEST: Beta-blocker Evaluation Survival Trial Purpose To determine whether the β-blocker bucindolol reduces morbidity and mortality in patients with advanced.
Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 FDA Presentation Advair Diskus 500/50 Carol Bosken, MD, ScM, MPH Medical Officer Division of Pulmonary.
1 Exploring Alternative Antibiotic Treatment Regimens: Methodology and Implications Dr. Tabish Hazir MASCOT Study Group 2 nd ICIUM Conference 2004.
Indiaclen Short course of Amoxicillin in treatment of Pneumonia (ISCAP) 3 versus 5 days amoxicillin for treatment of non-severe pneumonia in young children:
1 EFFICACY OF SHORT COURSE AMOXICILLIN FOR NON-SEVERE PNEUMONIA IN CHILDREN (Hazir T*, Latif E*, Qazi S** AND MASCOT Study Group) *Children’s Hospital,
Acute Otitis Media: Lessons Learned Thomas Smith, M.D. Division of Anti-Infective Drug Products.
Exacerbations. Exacerbations An exacerbation of COPD is an acute event characterized by a worsening of the patient’s respiratory symptoms that is beyond.
1 Recent Advances in Provision of Primary Care in the Public Sector: Is 3 Days of Oral Antibiotic Therapy Enough for Treatment of Ambulatory Pneumonia?
Acute Bacterial Otitis Media Summary and Charge to the Committee Renata Albrecht, M.D. Division of Special Pathogen and Immunologic Drug Products ODEIV,
History Taking Zinc code: UKACL1878ea Date of preparation May 2015 AstraZeneca provided funding & reviewed for technical accuracy.
CLINICAL EFFICACY Oral Telithromycin George Rochester, PhD, CCRN Statistical Reviewer Division of Biometrics III Division of Anti-infective Drug Products.
Lancet Respir Med 2013; 1: 199–209 R4.신재령 / Prof. 박명재
LSU Journal Club Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD WISDOM study H. Magnussen MD, et al. Nisha Loganantharaj, PGY1 April 21,
Prescribing for patients with COPD Evidence Update Emma Blanden- Pharmacist.
R3 정수웅. Introduction Community-acquired pneumonia − Leading infectious cause of death in developed countries − The mortality in patients with treatment.
Diamantis P. Kofteridis, Christina Alexopoulou, Antonios Valachis, Sofia Maraki, Dimitra Dimopoulou Clinical Infectious Diseases 2010; 51(11):1238–1244.
Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind,
Analysis of chronic obstructive pulomnary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK):
Post-discharge chemoprevention of malaria in transfused children; a randomized trial in Uganda & Kenya R Idro, R Opoka, A Dhabangi, F TerKuile, and K Phiri.
Hot Topics in Antibiotic Management of Pediatric CF Lung Disease Mike Tracy, MD Fellow, Pediatric Pulmonary.
LSU Journal Club Corticosteroid Therapy for Patients Hospitalized With Community-Acquired Pneumonia A Systematic Review and Meta-analysis Scott Hebert,
Management of stable chronic obstructive pulmonary disease (2) Seminar Training Primary Care Asthma + COPD D.Anan Esmail.
Tigecycline use in serious nosocomial infections: a drug use evaluation Matteo Bassetti*, Laura Nicolini, Ernestina Repetto, Elda Righi, Valerio Del Bono,
Depart. Of Pulmonology and Critical Care Medicine R4 백승숙.
The Relationship Between Chest Tube Size and Clinical Outcome in Pleural Infection Najib M. Rahman, Nicholas A. maskell, Christopher W. H. Davies, Emma.
Opiate Therapy in Chronic Cough Alyn H. Morice, Madhav S. Menon, Siobhan A. Mulrennan, Caroline F. Everett, Caroline Wright, Jennifer Jackson and Rachel.
1 Once-daily indacaterol versus twice-daily salmeterol for COPD ; a placebo-controlled comparison R2 정명화 Eur Respir J 2011; 37: 273–279.
CHEST 2013; 144(3): R3 김유진 / Prof. 장나은. Introduction 2  Cardiovascular diseases  common, serious comorbid conditions in patients with COPD cardiac.
Angela Aziz Donnelly April 5, 2016
Comparison between pathogen directed antibiotic treatment and empiri cal broad spectrum antibiotic treatment in patients with community acquired pneumonia.
APIC Chapter 13 Journal Club March 16, 2015 Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults NEJM – July 30, :5 Presented.
Fekri Abroug, Lamia Ouanes-Besbes, Mohamed Fkih-Hassen, Islem Ouanes, Samia Ayed, Laurent Brochard and Souheil ElAtrous Prednisone in COPD exacerbation.
18 Font Tex for Captions of Images/Charts/Graphs/Etc. AbstractMethods Background Implications References Results Background: Anecdotal evidence suggests.
Nitroxoline does not result in microbiological eradication in geriatric patients with lower urinary tract infection: a prospective cohort study C. Forstner1,2*,,
Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled.
Addition of Inhaled Tobramycin to Ciprofloxacin for Acute Exacerbations of Pseudomonas aeruginosa Infection in Adult Bronchiectasis* Diana Bilton, MD;
Miguel Angel Martı´nez-Garcı´a, MD; Juan-Jose Soler-Catalun˜ a, MD;
Sputum colour reported by patients is not a reliable marker of the presence of bacteria in acute exacerbations of chronic obstructive pulmonary disease 
بنام خداوند جان و خرد بنام خداوند جان و خرد.
West Essex Frailty Pathway: COPD
PRESENTER: Quynh vu, pgy-2
Stephanie Manning, Pharm.D. Candidate OUHSC College of Pharmacy
Presentation transcript:

Antibiotics in Addition to Systemic Corticosteroids for Acute Exacerbations of Chronic Obstructive Pulmonary Disease Johannes M.A. Daniels; Dominic snijders; Casper S. de Graaff Fer Vlaspolder; Henk M. Jansen; Wim G. Boersma (AJRCCM ; 181 : ) R2 Jang Na-eun Journal conference

Acute exacerbations of COPD (AECOPD) have considerable impact on morbidity, mortality, and quality of life - The role of bacteria in AECOPD is controversial - It is impossible for clinicians to distinguish infection from colonization - But, antibiotics are widely used to treat patients with AECOPD Several meta-analyses have confirmed the value of antimicrobial therapy - antibiotics seem to be most effective in patients with increased dyspnea, increased sputum volume, and increased sputum purulence - but, the trials were conducted several decades ago, before systemic steroids were widely introduced for the treatment of AECOPD BACKGROUND BACKGROUND

The role of antibiotics in acute exacerbations is controversial and their efficacy when added to systemic corticosteroids is unknown - unclear whether antibiotics have additional benefits when applied in patients with more severe exacerbation that are already treated with systemic corticosteroids

OBJECTIVES OBJECTIVES To determine the effects of doxycycline in addition to cortico- steroids on clinical outcome, microbiological outcome, lung function, and systemic inflammation in patients hospitalized with an acute exacerbation of chronic obstructive pulmonary disease

METHODS METHODS Research design A randomized, double-blind, placebo-controlled trial doxycycline in addition to systemic corticosteroids for patients hospitalized with an acute exacerbation of COPD - assess the effects of doxycycline on clinical and microbiological response, symptoms, lung function, and systemic inflammation (C-reative protein)

METHODS METHODS Participants - patients 45 years of age or older - COPD stages I-IV as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) - with acute (onset≤14d) exacerbation that required hospitalization (increased dyspnea, sputum volume, and sputum purulence) - most important exclusion criteria included fever(≥38.5 ℃ ) to prevent enrollment of patients with pneumonia, antibiotic treatment for at least 24 hours, and radiographic signs of pneumonia

METHODS METHODS Process - within 24 hours of admission, randomly receive a 7-day course of doxycycline or placebo : received 200mg of oral doxycycline - concomitant treatment consisted of IV prednisolone - other COPD medication was continued, exept for short-acting bronchodilators - attending physicians were unable to access the results of sputum cultures : but, when a pathogen was resistant to doxycycline, the physician was informed -> allowed to replace the study drug by an open label antibiotics

METHODS METHODS Outcomes and Follow-up - On Days 1, 10, and 30, assessment was performed - Assessment item : clinical and microbiological response, time to treatment failure, lung function, symptom scores, and serum C-reactive protein - The primary end point was clinical response on Day 30 - The secondary end point included clinical success on Day 10, clinical cure on Days 10 and 30, antibiotic treatment for lack of efficacy, lung function, time to treatment failure, serum CRP, symptoms, and micro-biological response

RESULTS RESULTS

Doxycycline showed superiority over placebo in terms of clinical success on Day 19, clinical cure on Day 10, Open label antibiotic treatment for lack of efficacy on Day 10 and symptoms on Day 10 (cough, sputum)

RESULTS RESULTS Time to treatment failure was not significantly difference in the doxycycline group and the placebo group

RESULTS RESULTS Doxycycline showed superiority over placebo in terms microbiological outcome For the three most predominant pathogens the success rates were significantly better in the doxycycline group

RESULTS RESULTS There was no interaction between the treatment effect and any of the subgroup variables (lung function, type of exacrbation, serum CRP, and bacterial presence) although there was a trend for patients with a high CRP value to benefit from antibiotic therapy

CONCLUSIONS CONCLUSIONS Doxycycline showed superiority in terms of clinical success and clinical cure on Day 10, microbiological success, the use of open label antibiotics(reduction of open label antibiotic therapy for lack of efficacy), and symptoms But, there are no significant difference in recovery of lung func- tion, sesolution of systemic infalmmation and time to treatment failure between the treatment groups

DISCUSSION DISCUSSION This trial has several features that were missing in other placebo- controlled trials. - the first placebo-controlled trial of antibiotics in addition to systemic corticosteroids for acute exacerbations of COPD - radiographic signs of pneumonia and fever were exclusion criteria to prevent enrollment of patients with pneumonia - sputum samples were collected before and after the inter-vention to allow a through microbiological work up